Patients ( n = @ ) with HER@-negative tumors of a median tumor size of @ cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel ( EC-T ) with or without eight infusions of bevacizumab every @ weeks before surgery .